Blue Trust Inc’s Denali Therapeutics DNLI Stock Holding History

Blue Trust Inc’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03K	Hold	40	–	–	﹤0.01%	2293
2026 Q1	$768	Hold	40	–	–	﹤0.01%	2293
2025 Q4	$660	Hold	40	–	–	﹤0.01%	2352
2025 Q3	$581	Hold	40	–	–	﹤0.01%	2402
2025 Q2	$560	Buy	+40	New	+$563	﹤0.01%	2306
2024 Q4	–	Sell	-72	Closed	-$1.67K	–	2579
2024 Q3	$1.67K	Sell	72 -10	-12%	-$248	﹤0.01%	2613
2024 Q2	$1.68K	Buy	+82	New	+$1.57K	﹤0.01%	2465
2023 Q3	–	Sell	-15	Closed	–	–	2094
2023 Q2	$0	Buy	15 +8	+114%	+$225	﹤0.01%	2130
2023 Q1	$0	Sell	7 -1	-13%	-$28	﹤0.01%	2382
2022 Q4	$0	Buy	8 +2	+33%	+$60	﹤0.01%	2289
2022 Q3	$0	Buy	+6	New	+$195	﹤0.01%	2145

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Trust Inc's DNLI Position: Q2 2026 in Review

Blue Trust Inc held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 40 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Blue Trust Inc first reported a position in DNLI in Q3 2022 and has held it in 11 quarters since. The position peaked at $1.68K in Q2 2024. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Blue Trust Inc held 40 shares of Denali Therapeutics worth $1.03K as of Q2 2026.
Blue Trust Inc left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2293 holding.
Blue Trust Inc first reported a position in Denali Therapeutics in Q3 2022 and has held it in 11 quarters since.
Blue Trust Inc's Denali Therapeutics position peaked at $1.68K in Q2 2024.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.